East London Times (ELT)East London Times (ELT)East London Times (ELT)
  • Local News
    • Redbridge News
    • Hackney News
    • Newham News
    • Havering News
    • Tower Hamlets News
    • Waltham Forest News
    • Barking and Dagenham News
  • Crime News​
    • Havering Crime News
    • Barking and Dagenham Crime News
    • Tower Hamlets Crime News
    • Newham Crime News
    • Redbridge Crime News
    • Hackney Crime News
    • Waltham Forest Crime News
  • Police News
    • Barking and Dagenham Police News
    • Havering Police News
    • Hackney Police News​
    • Newham Police News
    • Redbridge Police News
    • Tower Hamlets Police News
    • Waltham Forest Police News
  • Fire News
    • Barking and Dagenham Fire News
    • Havering Fire News
    • Hackney Fire News​
    • Newham Fire News
    • Redbridge Fire News
    • Tower Hamlets Fire News
    • Waltham Forest Fire News
  • Sports News
    • West Ham United News
    • Tower Hamlets FC News
    • Newham FC News
    • Sporting Bengal United News
    • Barking FC News
    • Hackney Wick FC News
    • Dagenham & Redbridge News
    • Leyton Orient News
    • Clapton FC News
    • Havering Hockey Club News
East London Times (ELT)East London Times (ELT)
  • Local News
  • Crime News​
  • Police News
  • Fire News
  • Sports News
  • Local News
    • Redbridge News
    • Hackney News
    • Newham News
    • Havering News
    • Tower Hamlets News
    • Waltham Forest News
    • Barking and Dagenham News
  • Crime News​
    • Havering Crime News
    • Barking and Dagenham Crime News
    • Tower Hamlets Crime News
    • Newham Crime News
    • Redbridge Crime News
    • Hackney Crime News
    • Waltham Forest Crime News
  • Police News
    • Barking and Dagenham Police News
    • Havering Police News
    • Hackney Police News​
    • Newham Police News
    • Redbridge Police News
    • Tower Hamlets Police News
    • Waltham Forest Police News
  • Fire News
    • Barking and Dagenham Fire News
    • Havering Fire News
    • Hackney Fire News​
    • Newham Fire News
    • Redbridge Fire News
    • Tower Hamlets Fire News
    • Waltham Forest Fire News
  • Sports News
    • West Ham United News
    • Tower Hamlets FC News
    • Newham FC News
    • Sporting Bengal United News
    • Barking FC News
    • Hackney Wick FC News
    • Dagenham & Redbridge News
    • Leyton Orient News
    • Clapton FC News
    • Havering Hockey Club News
  • Cookies Policy
  • Report an Error
  • Sitemap
  • Code of Ethics
  • Help & Resources
East London Times (ELT) © 2026 - All Rights Reserved
East London Times (ELT) > London News > Ellipses Pharma Targets £500m London Listing
London News

Ellipses Pharma Targets £500m London Listing

News Desk
Last updated: November 18, 2026 3:37 pm
News Desk
3 hours ago
Newsroom Staff -
@EastLondonTimes
Share
Ellipses Pharma Targets £500m London Listing
globalbankingandfinance.com · globalbankingandfinance.com

Key Points

  • Ellipses Pharma is exploring a London Stock Exchange listing through a proposed reverse takeover by Wolfram Resources.
  • The company has been reported as targeting a valuation of between £450 million and £500 million.
  • The proposed transaction is intended to bring Ellipses Pharma’s clinical-stage oncology portfolio to London’s Main Market.
  • An equity fundraising is expected alongside the transaction, which is targeted for completion in early 2027.
  • Final terms have not been agreed, and completion remains subject to due diligence, approvals and shareholder consent.

London (East London Times) November 18, 2026 – British cancer drug developer Ellipses Pharma said it is exploring a listing on the London Stock Exchange through a proposed reverse takeover by Wolfram Resources Plc. The transaction would involve Wolfram acquiring the entire issued share capital of Ellipses Pharma and seeking to re-list the enlarged group on the Main Market. The companies said an equity fundraising is also expected, with completion currently targeted for early 2027.

Contents
  • Key Points
  • What is Ellipses Pharma proposing?
  • What valuation and timetable have been reported?
  • What approvals are still required?
  • Why is the proposed listing significant?
  • What is the background to Ellipses Pharma’s development?
  • How could the development affect Ellipses Pharma’s London listing audience?

What is Ellipses Pharma proposing?

Ellipses Pharma and Wolfram Resources have signed a non-binding memorandum of understanding covering the proposed acquisition and re-listing. Consideration is expected to be satisfied through the issue of new Wolfram ordinary shares, although the final terms will be agreed after technical, financial and legal due diligence.

Ellipses Pharma’s pipeline includes clinical programmes targeting non-small-cell lung cancer and breast cancer. The proposed transaction would bring its clinical-stage oncology portfolio to the Main Market in the commercial companies listing category.

What valuation and timetable have been reported?

Reuters reported that Ellipses Pharma is targeting a valuation of between £450 million and £500 million, equivalent to approximately $594 million to $660 million. The report attributed the valuation range to an earlier Times report.

The companies said they are targeting completion of the proposed acquisition, fundraising and re-listing in early 2027. Business Live previously reported that the transaction could take place as early as February and that Berenberg was reported to have been appointed to oversee the deal, although those details were not included in the companies’ formal announcement.

What approvals are still required?

Wolfram Resources said the transaction remains conditional on satisfactory due diligence, agreement of final terms and definitive documentation. It also requires Financial Conduct Authority approval and publication of a prospectus, shareholder approval, relevant approval from the Panel on Takeovers and Mergers, and admission of the enlarged share capital to the Official List and the London Stock Exchange Main Market.

The companies cautioned that there is no certainty the proposed transaction will proceed or that it will proceed on the terms currently under consideration.

Why is the proposed listing significant?

Ellipses Pharma founder and chair Sir Chris Evans said a reverse takeover listing could help the company raise additional capital from public-market investors. The fundraising would give the clinical-stage developer access to capital markets while it advances its oncology programmes, although the amount and terms of any fundraising have not been disclosed.

What is the background to Ellipses Pharma’s development?

Ellipses Pharma was established in 2017 as a London-based global oncology drug development company. Its development pipeline includes programmes for non-small-cell lung cancer and breast cancer. Wolfram Resources is a Main Market-listed special purpose acquisition company whose shares have traded in the shell companies category. The proposed deal would change the enlarged group’s intended listing category to commercial companies, subject to regulatory and shareholder approvals.

How could the development affect Ellipses Pharma’s London listing audience?

For investors who follow British cancer drug developer Ellipses Pharma considers London listing developments, the proposed transaction could provide a public-market route to exposure to a clinical-stage oncology business. The expected fundraising may increase the company’s available capital, but it could also affect ownership through the issue of new shares.

London-listed biotechnology investors are likely to assess the company’s clinical evidence, development timetable, funding requirements and regulatory risks before any investment decision. Because the valuation, fundraising terms and definitive transaction documents have not been agreed, the potential effect on the company and its prospective audience cannot yet be determined.

London Halal Forum 2026 Brings Global Leaders Together to Explore the Future of the Halal Economy
London Halal Forum 2026 to Explore Global Growth, Investment and the Expanding Halal Economy
Two Men Charged After Hotel Assault in London
From Importer to Producer: Saudi Arabia’s Halal Ambitions Take Centre Stage in London
News Desk
ByNews Desk
Follow:
Independent voice of East London, delivering timely news, local insights, politics, business, and community stories with accuracy and impact.
Previous Article NBC News Marks 100 Years of Broadcasting in New York NBC News Marks 100 Years of Broadcasting in New York
Next Article Peter Hindmarsh Barred During Lucy Letby Trial, Manchester Peter Hindmarsh Barred During Lucy Letby Trial, Manchester
East London Times footer logo

All the day’s headlines and highlights from East London Times, direct to you every morning.

Area We Cover

  • Hackney News
  • Havering News
  • Newham News
  • South East London News
  • Redbridge News
  • Tower Hamlets News
  • Waltham Forest News

Explore News

  • Crime News​
  • Fire News
  • Police News
  • Live Traffic & Travel News
  • Sports News

Discover ELT

  • About East London Times (ELT)
  • Become ELT Reporter
  • Contact East London Times (ELT)
  • Street Journalism Training Programme (Online Course)
  • Politicians
  • Journalists
  • Contributors

Useful Links

  • Cookies Policy
  • Report an Error
  • Sitemap
  • Code of Ethics
  • Help & Resources
East London Times (ELT) © 2026 - All Rights Reserved
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?